Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed
A bi-partisan amendment to promote research into psychedelics has passed a vote in the U.S. House of Representatives.
The House also passed an amendment from Democrat Lou Correa (D-CA) and Republican Jack Bergman (R-MI) that would encourage research into psychedelic substances such as psilocybin and MDMA.
A study using Compass Pathways’ COMP360 psilocybin compound for anorexia was published in Nature Medicine. The results showed 40% of patients with a significant reduction in eating disorder psychopathology after three months. Although the sample size was small, the results do show promise for a condition with no successful treatment options and high rates of suicide or other serious issues.
Results from a phase 3 trial show that generic ketamine was safe and effective in treating patients with treatment-resistant depression.
The double-blind, randomized, active-controlled multicentre trial was conducted at seven mood disorder centres in Australia and New Zealand. Results were published in The British Journal of Psychiatry and online in the Cambridge University Press.
Small Pharma has published its financial results for the fiscal first quarter ended May 31, 2023
- Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023
- Potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024, based on clinical findings across SPL026 and SPL028 programs to date
- SPL026 Phase IIa clinical trial results well-received at several international scientific conferences
- Anticipated cash runway to at least Q4 2024 following recent operational restructuring
“The completion of CYB003 dosing in Cohort 5 represents a significant milestone in the progression of our Phase 2 study, taking us one step closer towards establishing a therapeutically efficacious dose and advancing CYB003 towards pivotal studies with the goal of bringing CYB003 as a differentiated and rapid-acting therapeutic option for people with major depressive disorder,” said Doug Drysdale, Chief Executive Officer of Cybin. “We are proud of the speed with which we have advanced our clinical-stage programs and remain on track to deliver topline efficacy data from this Phase 2 study later this year and submit data to the FDA in preparation for a potential pivotal study of CYB003.”